Pipeline—creating tomorrow's vaccines today

The world urgently needs new tools to help solve some of our greatest infectious disease challenges. At Novavax we are applying our unique technology to address current and emerging threats.

Novavax continually conducts clinical trials and investigations and gathers real-world evidence to develop vaccines aimed at addressing public health threats. Our scientists in our research and development (R&D) programs are committed to the efficient delivery of new vaccines while maintaining the safety of patients who take part in our trials.

Our pipeline

Novavax aims to develop innovative vaccines that may help improve lives and fight infectious diseases around the world. The table below lists our selected research and development priorities.

Our Matrix-M adjuvant technology

Investigational vaccines listed below with the Matrix-M symbol have been developed with the Matrix-M adjuvant.

Learn more about our technology platform

Vaccines in Novavax Pipeline and Status
Therapeutic area	Candidate	Adjuvant Technology	Phase of trial				Authorized use
			Preclinical	Phase 1	Phase 2	Phase 3
Novavax Clinical/Commercial Stage
Respiratory diseases COVID-19	Novavax COVID-19 vaccine	Matrix-M™ adjuvant					Authorized¹
Novavax Clinical Stage
Respiratory diseases COVID-19 + seasonal influenza	COVID-influenza combination (CIC) vaccine	Matrix-M™ adjuvant			Phase 2
Partnered Commercial Stage
Parasitic diseases Malaria	R21/Matrix-M^＊	Matrix-M™ adjuvant					Authorized²

Respiratory diseases

COVID-19

Novavax COVID-19 vaccine

Authorized¹

Matrix-M™ adjuvant

Novavax Clinical/Commercial Stage

Respiratory diseases

COVID-19 + seasonal influenza

COVID-influenza combination (CIC) vaccine

Phase 2

Matrix-M™ adjuvant

Novavax Clinical Stage

Parasitic diseases

Malaria

R21/Matrix-M^＊

Authorized²

Matrix-M™ adjuvant

Partnered Commercial Stage

¹Authorized in select geographies under trade names Novavax COVID-19 Vaccine, Adjuvanted; Covovax™; and Nuvaxovid™, authorized in the U.S. under trade name, Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula); and authorized in the EU under the trade name Nuvaxovid XBB.1.5. Strain change trials for the COVID-19 vaccines ongoing. Authorization information can be found by country at https://novavaxcovidvaccine.com.

²Authorized in Ghana, Nigeria, and Burkina Faso; Commercialized by Serum Institute of India and granted prequalification by the WHO.

＊Developed and distributed by Oxford University and Serum Institute of India, using licensed Matrix-M technology.